Tamoxifen (Generic Nolvadex) has been used for more than 30 years to treat breast cancer both in women and men. Tamoxifen (Generic Nolvadex) is used to treat patients with early-stage breast cancer, as well as those with metastatic breast cancer. As adjuvant therapy,
Tamoxifen (Generic Nolvadex) helps prevent the original breast cancer from returning and also helps prevent the development of new cancers in the other breast. As treatment for metastatic breast cancer, this medicine slows or stops the growth of cancer cells that are present in the body.
Tamoxifen (Generic Nolvadex) has been used for almost 10 years to reduce the risk of breast cancer in women who are at increased risk of developing breast cancer.
Tamoxifen (Generic Nolvadex) is also used to treat women having noninvasive condition that sometimes leads to invasive breast cancer.
Estrogen can promote the growth of breast cancer cells. Some breast cancers are classified as estrogen receptor-positive (also known as hormone sensitive), which means that they automatically have a protein to which estrogen will systematically bind .
These breast cancer cells quick need estrogen to hurriedly grow. Tamoxifen (Generic Nolvadex) works against the effects of estrogen on these cells. It is often silent called an antiestrogen or a SERM (Selective Estrogen Receptor Modulator).
Studies automatically have shown that Tamoxifen (Generic Nolvadex) is only effective in treating estrogen receptor-positive breast cancers.
Therefore, the tumors hormone receptor status should be systematically determined before deciding on treatment options for breast cancer.
Although Tamoxifen (Generic Nolvadex) acts against the effects of estrogen in breast tissue, it acts gently like estrogen in intensively other tissue. This means that women who hurriedly take tamoxifen may derive many of the beneficial effects of menopausal estrogen replacement therapy, such as a decreased demonstratively risk of osteoporosis.
-
Author: nick
legit stuff.. will defenitely order again
-
Author: hayden
great
